Dr. Lebenthal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-534-7513
Summary
- Justin Lebenthal, MD is an Oncologist based in Houston, TX. His education includes a Residency in Internal Medicine from New York Presbyterian Hospital (Cornell Campus) from 2018 to 2021, a Fellowship in Hematology and Medical Oncology at University of Texas Health Science Center at Houston/M D Anderson Cancer Center from 2021 to 2024, and he's a class of 2018 graduate from Rutgers Robert Wood Johnson Medical School. He has multiple publications including in Clinical Cancer Research and Cancer Treatment and Research Communications, some of which have been frequently cited by other publications.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2021 - 2024
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2018 - 2021
Rutgers Robert Wood Johnson Medical SchoolClass of 2018
Certifications & Licensure
NY State Medical License 2024 - 2026
TX State Medical License 2021 - 2024
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation.Sandra L Grimm, Menuka Karki, Kyle A Blum, Jean-Philippe Bertocchio, Rong He
Clinical Cancer Research. 2025-01-21 - 1 citationsClinical Characteristics, Management, and Outcomes of Patients with Renal Medullary Carcinoma: A Single-center Retrospective Analysis of 135 Patients.Justin M Lebenthal, Panayiotis D Kontoyiannis, Andrew W Hahn, Zita D Lim, Priya Rao
European Urology Oncology. 2024-07-15 - 1 citationsA Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer.Ana M Aparicio, Rebecca S S Tidwell, Shalini S Yadav, Jiun-Sheng Chen, Miao Zhang
Clinical Cancer Research. 2024-07-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
